Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Gross Margin (2016)

Historic Gross Margin for Viridian Therapeutics, Inc.\DE (VRDN) over the last 3 years, with Q4 2016 value amounting to 35.95%.

  • Viridian Therapeutics, Inc.\DE's Gross Margin fell 535600.0% to 35.95% in Q4 2016 from the same period last year, while for Dec 2016 it was 26.72%, marking a year-over-year decrease of 26900.0%. This contributed to the annual value of 26.72% for FY2016, which is 275500.0% up from last year.
  • Per Viridian Therapeutics, Inc.\DE's latest filing, its Gross Margin stood at 35.95% for Q4 2016, which was down 535600.0% from 36.0% recorded in Q3 2016.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Gross Margin ranged from a high of 53.47% in Q2 2015 and a low of 58.88% during Q3 2015
  • Its 3-year average for Gross Margin is 26.8%, with a median of 41.72% in 2014.
  • As far as peak fluctuations go, Viridian Therapeutics, Inc.\DE's Gross Margin plummeted by -1108100bps in 2015, and later surged by 948900bps in 2016.
  • Over the past 3 years, Viridian Therapeutics, Inc.\DE's Gross Margin (Quarter) stood at 48.18% in 2014, then plummeted by -63bps to 17.6% in 2015, then plummeted by -304bps to 35.95% in 2016.
  • Its Gross Margin stands at 35.95% for Q4 2016, versus 36.0% for Q3 2016 and 43.68% for Q2 2016.